16 completed, 7 unknown, 6 recruiting, 5 terminated. 13 Phase 1, 13 Phase 2, 6 Not applicable, 5 Phase 3, 2 Early Phase 1.
Follow Myeloid Leukemia: new trials by email Literature Review of Myeloid Leukemia trials Research Report on Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2026-11-30 | 2026-10-13 |
| Halt Aging in Survivors of Blood Cancers Behavioral Coaching Intervention, Virtual Exercise Platform - Hematological Malignancy, Leukemia | Not applicable | Recruiting | University of Nebraska | 180 | 2026-04-09 | 2026-07-01 |
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML 131I-apamistamab, Fludarabine, Cyclophosphamide - Acute Leukemia, Myeloid Leukemia | Phase 2 / Phase 3 | Not yet recruiting | Actinium Pharmaceuticals | 306 | 2026-01-01 | 2025-09-10 |
| Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia Venetoclax, Azacitidine, Mitoxantrone - Leukemia, Myeloid Leukemia | Phase 1 | Recruiting | University of Colorado, Denver | 30 | 2024-07-21 | 2026-01-15 |
| A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Gilteritinib, Momelotinib - Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-05-22 | 2026-10-05 |
| Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML Interviews - Myeloid Leukemia | Withdrawn | Centre Hospitalier Régional Metz-Thionville | 2024-05-15 | 2024-05-23 | ||
| Integrated Actionable Aging Assessment for Cancer Patients Pilot Assessment tool IA3-CP with SDoH, Assessment tool IA3-CP without SDoH - Breast Cancer, Hodgkin Lymphoma | Not applicable | Active not recruiting | University of Colorado, Denver | 35 | 2024-03-01 | 2025-09-15 |
| Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT IFN-Α - Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Recruiting | Peking University People's Hospital | 35 | 2024-01-01 | 2025-06-03 |
| Frequency and Risk Factors of Acute Myeloid Leukemia Bone marrow aspirite for diagnosis - Myeloid Leukemia | Unknown | Assiut University | 200 | 2023-05-01 | 2023-03-28 | |
| Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors Nicotinamide Riboside, Placebo, Exercise Intervention - Lymphoblastic Leukemia, Cancer Survivors | Phase 2 | Recruiting | Children's Hospital of Philadelphia | 80 | 2023-02-23 | 2025-12-04 |
| FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia Daratumumab/rHuPH20, FT538, Fludarabine - Acute Myeloid Leukemia, Myeloid Leukemia | Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 9 | 2021-11-03 | 2024-10-24 |
| Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors Biopsy, Biospecimen Collection, Electronic Health Record Review - Acute Myeloid Leukemia, Myeloid Leukemia | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 10 | 2021-06-30 | 2026-09-22 |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation IFN-γ (interferon gamma-1b) injection - Myelodysplastic Syndromes, Myeloid Leukemia | Early Phase 1 | Completed | Sawa Ito, MD | 8 | 2021-03-08 | 2025-04-29 |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab - Leukemia, Myeloid, Chronic, Myeloid Leukemia | Phase 1 | Recruiting | Ascentage Pharma Group Inc. | 242 | 2020-01-09 | 2025-11-05 |
| Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland Bosutinib - Myeloid Leukemia | Completed | Pfizer | 17 | 2019-05-01 | 2026-06-29 | |
| Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients Intravenous (IV) and oral Vitamin C - Lymphoid Leukemia, Myeloid Leukemia | Phase 2 | Completed | Virginia Commonwealth University | 61 | 2018-10-01 | 2023-11-07 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies CAR-T cell immunotherapy - B-cell Acute Lymphoblastic Leukemia, Lymphoma | Phase 1 / Phase 2 | Unknown | Shenzhen BinDeBio Ltd. | 73 | 2018-03-01 | 2019-12-11 |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery Behavioral techniques - Hodgkin Lymphoma, Non-Hodgkin Lymphoma | Not applicable | Completed | University of Wisconsin, Madison | 39 | 2016-12-22 | 2019-11-15 |
| NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents cyclophosphamide, Fludarabine, NK cell infusion - Acute Myeloid Leukemia, Leukemia | Phase 2 | Completed | Instituto de Investigación Hospital Universitario La Paz | 7 | 2016-05-01 | 2020-10-05 |
| Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation EXJADE - Myeloid Leukemia, Myelodysplastic Syndromes | Unknown | Hospices Civils de Lyon | 150 | 2016-04-01 | 2018-09-06 |
Showing 20 of 39. Sign in to see all of them.
Leukemia, Myeloid (39) · Leukemia, Myeloid, Acute (17) · Myelodysplastic Syndromes (13) · Leukemia (11) · Multiple Myeloma (8) · Hodgkin Disease (6) · Leukemia, Lymphoid (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Graft vs Host Disease (5) · Leukemia, Monocytic, Acute (5) · Lymphoma, Non-Hodgkin (5) · Hematologic Neoplasms (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Burkitt Lymphoma (3)
Hematologic Diseases (39) · Hemic and Lymphatic Diseases (39) · Neoplasms by Histologic Type (39) · Neoplasms (38) · Leukemia (28) · Bone Marrow Diseases (15) · Immune System Diseases (14) · Immunoproliferative Disorders (13) · Lymphatic Diseases (13) · Lymphoproliferative Disorders (13) · Pathological Conditions, Signs and Symptoms (9) · Blood Protein Disorders (8) · Cardiovascular Diseases (8) · Hemorrhagic Disorders (8) · Hemostatic Disorders (8)
Cyclophosphamide (4) · fludarabine (4) · fludarabine phosphate (3) · Azacitidine (2) · Behavior Therapy (2) · Filgrastim (2) · Idarubicin (2) · Whole-Body Irradiation (2) · blinatumomab (2) · venetoclax (2) · 2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate (1) · AVE9633 (1) · Anthracyclines (1) · Ascorbic Acid (1) · Biopsy (1)
M.D. Anderson Cancer Center (3) · Amgen (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Samsung Medical Center (2) · Technische Universität Dresden (2) · University of Colorado, Denver (2) · University of Wisconsin, Madison (2) · Actinium Pharmaceuticals (1) · Ascentage Pharma Group Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · Assiut University (1) · AstraZeneca (1) · Barbara Ann Karmanos Cancer Institute (1) · Celgene Corporation (1) · Centre Hospitalier Régional Metz-Thionville (1)
United States (23) · France (4) · Germany (4) · Canada (2) · China (2) · Italy (2) · Netherlands (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Switzerland (1)
Dong Hwan Kim, M.D.,Ph.D. (2) · A. John Barrett, M.D. (1) · Abhinav Deol, M.D. (1) · Andrea Velardi, MD (1) · Andrew Kent, MD, PhD (1) · Bob Lowenberg, MD, PhD (1) · Bouthaina S Dabaja (1) · Denis-Claude Roy, MD (1) · Dirk Reinhardt, Prof. Dr. med. (1) · Dolores Grosso, RN, CRNP, DNP (1) · Erin Costanzo (1) · Erin Costanzo, MD (1)
PMID 18083847, PMID 18182574, PMID 18616811, PMID 21480469, PMID 21976672, PMID 22877506, PMID 23704089, PMID 26202768, PMID 26814618, PMID 27269945, PMID 31919123, PMID 33610500, PMID 35854224, PMID 35982483, PMID 37085674, PMID 39570620, PMID 40803346
4UL1TR000427-10 (2), P30CA014520 (2), 2015 (1), K07CA136966 (1), P50CA244688 (1), R01CA254955 (1)